Publication:

Assessment of pharmacogenomic agreement

Loading...
Thumbnail Image

Open/View Files

Date

2016

Journal Title

Journal ISSN

Volume Title

Publisher

F1000Research
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Safikhani, Z., N. El-Hachem, R. Quevedo, P. Smirnov, A. Goldenberg, N. Juul Birkbak, C. Mason, et al. 2016. “Assessment of pharmacogenomic agreement.” F1000Research 5 (1): 825. doi:10.12688/f1000research.8705.1. http://dx.doi.org/10.12688/f1000research.8705.1.

Abstract

In 2013 we published an analysis demonstrating that drug response data and gene-drug associations reported in two independent large-scale pharmacogenomic screens, Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE), were inconsistent. The GDSC and CCLE investigators recently reported that their respective studies exhibit reasonable agreement and yield similar molecular predictors of drug response, seemingly contradicting our previous findings. Reanalyzing the authors’ published methods and results, we found that their analysis failed to account for variability in the genomic data and more importantly compared different drug sensitivity measures from each study, which substantially deviate from our more stringent consistency assessment. Our comparison of the most updated genomic and pharmacological data from the GDSC and CCLE confirms our published findings that the measures of drug response reported by these two groups are not consistent. We believe that a principled approach to assess the reproducibility of drug sensitivity predictors is necessary before envisioning their translation into clinical settings.

Description

Research Data

Keywords

Articles, Bioinformatics, Genomics, Methods for Diagnostic & Therapeutic Studies, Molecular Pharmacology, Pharmacogenomics, Pharmacokinetics & Drug Delivery, Statistical Methodologies & Health Informatics, Cancer Cell Lines, High-Throughput Screening, Biomarkers, Drug Response, Experimental Design, Statistics

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories